RT Journal Article
T1 Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.
A1 Puig, Noemi
A1 Contreras, Maria-Teresa
A1 Agullo, Cristina
A1 Martinez-Lopez, Joaquin
A1 Oriol, Albert
A1 Blanchard, Maria-Jesus
A1 Rios, Rafael
A1 Martin, Jesus
A1 Iñigo, Maria-Belen
A1 Sureda, Anna
A1 Hernandez, Miguel-Teodoro
A1 de la Rubia, Javier
A1 Gonzalez-Calle, Veronica
A1 Krsnik, Isabel
A1 Cabañas, Valentin
A1 Palomera, Luis
A1 Moraleda, Jose-Maria
A1 Bargay, Joan
A1 Cedena, Maria-Teresa
A1 Paiva, Bruno
A1 Rosiñol, Laura
A1 Blade, Joan
A1 San Miguel, Jesus
A1 Lahuerta, Juan-Jose
A1 Mateos, Maria-Victoria
K1 Antibodies, Monoclonal
K1 Immunoglobulin Light Chains
K1 Transplantation, Autologous
AB Monitoring of the monoclonal protein (M-protein) by electrophoresis and/or immunofixation (IFE) has long been used to assess treatment response in multiple myeloma (MM). However, with the use of highly effective therapies, the M-protein becomes frequently undetectable, and more sensitive methods had to be explored. We applied IFE and mass spectrometry (EXENT&FLC-MS) in serum samples from newly diagnosed MM patients enrolled in the PETHEMA/GEM2012MENOS65 obtained at baseline (n = 223), and after induction (n = 183), autologous stem cell transplantation (n = 173), and consolidation (n = 173). At baseline, the isotypes identified with both methods fully matched in 82.1% of samples; in the rest but 2 cases, EXENT&FLC-MS provided additional information to IFE with regards to the M-protein(s). Overall, the results of EXENT&FLC-MS and IFE were concordant in >80% of cases, being most discordances due to EXENT&FLC-MS+ but IFE- cases. After consolidation, IFE was not able to discriminate 2 cohorts with different median progression-free survival (PFS), but EXENT&FLC-MS did so; furthermore, among IFE- patients, EXENT&FLC-MS identified 2 groups with significantly different median PFS (P = .0008). In conclusion, compared with IFE, EXENT&FLC-MS is more sensitive to detect the M-protein of patients with MM, both at baseline and during treatment, and provides a more accurate prediction of patients' outcome. This trial was registered at www.clinicaltrials.gov as #NCT01916252.
PB American Society of Hematology
YR 2022
FD 2022-02-07
LK http://hdl.handle.net/10668/20250
UL http://hdl.handle.net/10668/20250
LA en
NO Puig N, Contreras MT, Agulló C, Martínez-López J, Oriol A, Blanchard MJ, et al. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. Blood Adv. 2022 Jun 14;6(11):3234-3239.
DS RISalud
RD Apr 7, 2025